Dish of the day
No Joiners Today
Off the menu
No Leavers Today
What’s cooking in the IPO kitchen?
Caribbean Investment Holdings. Incorporated in Belize . CIHL primarily operates financial services businesses through its subsidiaries The Belize Bank Limited and Belize Bank International Limited, both located in Belize and international corporate services through Belize Corporate Services Limited. CIHL shares are also traded on the Bermuda Stock Exchange. Lord Ashcroft holds 75%. No capital raise. Due 28 April. £36m . 2019 net profit US$ 10.7m
DXS International* 10p £4.8m (AQSE:DXSP)
Update on measures taken by the Company in response to COVID-19 and confirms that during this unprecedented interruption to business, DXS is continuing to deliver support of its solutions to frontline primary care doctors and nurses.
Being an accredited NHS solutions provider, DXS has well-established business continuity and disaster recovery protocols in place. These were triggered during the early stages of the COVID-19 outbreak and at this point, 95% percent of staff, both in the United Kingdom and South Africa are successfully working from home and the company remains fully operational. DXS has supported national efforts to combat the pandemic by launching a clinical decision support toolkit via our DXS Point of Care solution for COVID-19 treatment and information. This is being used by doctors and nurses in the diagnosis and treatment of the disease.
Implemented support process designed to help clinicians access the Clinical Decision Support solution while working from home. The pandemic has placed a sharp focus on the necessity for health authorities to strongly consider digital health solutions such as those provided by DXS Point of Care and in particular the new ExpertCare solution for the management of hypertension, which has been identified as a high risk factor for those patients contracting COVID19. “Although it is clear that the current situation has impacted our anticipated revenue growth in the current financial year, we are on track to match our previous years revenue. We are fortunate to have a recurring revenue stream that has enabled the business to continue delivering our service with minimum disruption to staff. Some product launches, ExpertCare, MyVytalCare and CompleteCare have seen delays given the NHS’s focus on COVID-19, and it is not possible to predict the point at which new growth will begin. However with cash in the bank and sound products we remain optimistic about the future growth of the business and will update the market as soon as possible once there is more clarity on the situation.”
Crossword Cybersecurity* 275p £12.9m (AIM:CCS)
FY Dec 19 results. Revenue at £1.3m was in line with expectations, a rise of 22%. Encouragingly the 51% increase in own product and consulting revenue more than offset the decline in non-core software development. Sales pipeline now at £6m. Cash balances of £1.5m. Crossword raised funds of £1.275m via a convertible loan note in the period followed by a further issuance of £0.125m in January. Earlier this month Crossword announced that it had undertaken a placing and subscription of £1m, including an intended subscription by the founder and CEO Tom Ilube, which was formalised in an RNS today after the results were announced.
Solo Oil 0.925 £5.8m (AIM:SOLO)
Update regarding its 25% non-operated interest in Ruvuma PSA Joint Venture in Tanzania. Solo has received confirmation from the Operator, Ndovu Resources Limited, that the Mtwara Exploration Licence, which sits within the Ruvuma PSA, and contains the Ntorya Gas field has been formally extended by the Ministry of Energy of Tanzania. The key terms of the extension are as anticipated and consistent with those previously set out. It is acknowledged by all parties that the full work programme is unlikely to be completed during this extension period and Solo understands that the Operator will therefore apply for an additional extension as necessary and as permissible under the current legislation. In the meantime, the Company, with its JV partners, will continue to prepare for this work programme.
As previously announced on 2 March 2020, the Board launched a formal process to explore value realisation options for its assets in Tanzania. The Company has seen an encouraging level of interest in its Tanzanian assets and a number of interested parties have requested access to the data room.
Yellow Cake 221.75p £195m (AIM:YCA)
Specialist company operating in the uranium sector with a view to holding physical uranium for the long term, notes the release of the U.S. Nuclear Fuel Working Group’s report: “Restoring America’s Competitive Nuclear Energy Advantage – A Strategy to Restore American Nuclear Energy Leadership”.
The report outlines a strategy to re-establish capabilities and provide direct support to the front end of America’s nuclear fuel cycle, including direct purchases of uranium for the strategic Uranium Reserve.
The report includes policy recommendations on Executive, Congressional and regulatory actions that could be taken to enhance the positive attributes of nuclear power, revive capabilities of the uranium mining, milling and conversion industries in the U.S., strengthen U.S. technology supremacy, and drive U.S. exports, while assuring consistency with U.S. non-proliferation objectives and supporting national security.
Property Franchise Group 162.5p £40m (LON:TPFG)
Further to the Company’s appointment of Gareth Samples as CEO Designate in February 2020, the Company announced that Gareth will formally be appointed to the Board as CEO with effect from 30 April 2020.
Since the time of his appointment Gareth has been working alongside current CEO Ian Wilson, communicating with franchisees, participating in the recent final results investor roadshow and critically, forming strategy on the business’ response to the impact of COVID-19. With an orderly transfer of responsibilities having been completed Ian will step down from the Board and retire on 30 April 2020. With 30 years’ property industry experience Gareth brings a wealth of knowledge to the Group. The Board welcomes his leadership at this challenging time for the industry, brought about by COVID-19.
Directa Plus 81.5p £49.7m (AIM:DCTA)
The producer and supplier of graphene nanoplatelets based products for use in consumer and industrial markets, announces that the Company has been granted an EU-wide patent covering the use of its graphene based Grafysorber® technology for treating waters and sludges contaminated by hydrocarbons. Grafysorber® is sustainably produced, non-flammable and reusable, with the adsorbed hydrocarbons recoverable.
The field of application granted in the patent covers produced waters, refinery waters, and, in general, any kind of wastewater which contains relatively low but still dangerous amount of hydrocarbons. Such waters are generally very difficult to treat and often expensive and complex, involving multiple step processes that in most cases must be specific for each type of hydrocarbon. By contrast, the Company’s Grafysorber® adsorbant offers an effective and quick one-step process, that simply mixes the water to be treated with Grafysorber® and then allows the contaminants to be recovered.
Positive decision document in respect of the testing of the West Newton A-2 well (“WNA-2”) on PEDL183 has been received from the Environment Agency by Rathlin Energy (UK) Limited , the Operator. This variation will allow Rathlin to use mechanical methods (pumpjack/nodding donkey) for lifting wellbore fluids and for the utilisation of a smaller incineration unit during the testing of the WNA-2 well. Testing operations at West Newton will recommence once government guidance pertaining to COVID-19 permits, the required personnel and equipment become available, and the continued health and safety of Rathlin employees, contract personnel and the community can be ensured.
88 Energy 0.25p £17.8m (AIM:88E)
Intention to make an off-market takeover offer to acquire all of the fully paid ordinary shares and listed options on issue in XCD Energy Limited (ASX: XCD) , an oil exploration company with operations on the North Slope of Alaska, USA.
· 88 Energy’s Offer is:
– 1.67 new 88 Energy shares for every XCD Energy share held (“Share Offer”); and
– 0.5 new 88 Energy shares for every XCD Energy listed option held (“Option Offer”),
(together, “the ProposedOffers”).
· Share Offer values the XCD Energy shares at 1.0 cent each1, representing a:
– 100% premium to the closing price of XCD Energy shares on ASX on 24 April 2020 of 0.5 cents;
The merger creates an Alaska focused oil explorer with:
– a diversified portfolio of 3 key project areas; Project Icewine, Yukon Leases and Project Peregrine at various stages of project maturity;
Deltex Medical 2p £10.5m (DEMG.L)
FY Dec 19 results. the Group posted an operating profit (excluding exceptional items) of £90,000 (2018: loss £943,000) – an improvement of £1 million
§ positive adjusted EBITDA of £0.4 million (2018: loss £0.7 million)
§ revenues £4.3 million (2018: £5.0 million), reflecting a focus on profitable business, lower sales & marketing spend and cessation of a third-party distribution agreement
§ demand increasing for Deltex Medical TrueVue Doppler systems in intensive care units in the UK and USA as a result of the COVID-19 pandemic
§ reduced demand in Q1 for the Group’s Doppler probes from operating rooms – due to cancellation of elective surgery in anticipation of COVID-19; although increased demand associated with “catch-up” expected later in the year
Ananda Dev 0.16p £0.7m (AQSE:ANA)
Update to shareholders.
* Current application to grow medicinal cannabis will involve analysis of cannabis strains at the laboratory of Dr Dedi Meiri at The Technion in Israel
* Dr Meiri is considered one of the world’s foremost cannabis scientists
* Dr Meiri has commenced a new project to assess the potential of the anti inflammatory properties of cannabis for treating coronaviruses
* Ananda’s application to grow medicinal cannabis will be broadened to stabilise strains of cannabis which may have applicability for the treatment of hyperinflammation caused by coronaviruses. These strains would be analysed at Dr Meiri’s lab
*denotes a corporate client of Hybridan LLP
0203 764 2344